Impact of the change in urinary and sexual function on health-related quality of life after once daily low-dose mirodenafil treatment in patients with organic erectile dysfunction.
OBJECTIVE
We aimed to evaluate whether changes in urinary and sexual function can influence health-related quality of life.


METHODS
Out of 54 recruited patients, 36 were enrolled, and data for 30 participants with erectile dysfunction were available. At baseline and after 1 and 2 months, each participant completed the International Index of Erectile Function (IIEF-15), the International Prostate Symptom Score (IPSS) and the Medical Outcomes Study Short-Form 36-Item Health Survey (SF-36). Uroflowmetry, post-voiding residual volume and the nocturnal penile tumescence (NPT) test were performed at baseline and at the study's conclusion.


RESULTS
Compared with baseline, the IPSS, IIEF-15, peak urinary flow rate, NPT parameters and mental component of the SF-36 exhibited significant improvement at the study's conclusion. Among the symptomatic parameters, the changes in the storage and erectile function parameters contributed significantly to the change in the mental component score on the SF-36 (p = 0.007, R(2) = 0.502).


CONCLUSIONS
The daily administration of low-dose mirodenafil (50 mg) produced improvements in urinary and erectile function with or without sexual stimulation. Furthermore, this therapy enhanced the mental component of health-related quality of life by improving storage and erectile symptoms.
Department of Urology, St. Vincent's Hospital, The Catholic University of Korea, Suwon, South Korea.
Dong Sup
DS
Lee
Hyun-Sop
HS
Choe
Sae Woong
SW
Kim
Kee Uk
KU
Jung
Seung-Ju
SJ
Lee
D000328:Adult; D007172:Erectile Dysfunction / Q000188:drug therapy* / Q000523:psychology*; D006801:Humans; D059411:Lower Urinary Tract Symptoms; D008297:Male; D008875:Middle Aged; D010410:Penile Erection; D058986:Phosphodiesterase 5 Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D011446:Prospective Studies; D011467:Prostate / Q000503:physiopathology; D011744:Pyrimidinones / Q000008:administration & dosage / Q000627:therapeutic use*; D011788:Quality of Life; D013449:Sulfonamides / Q000008:administration & dosage / Q000627:therapeutic use*; D011795:Surveys and Questionnaires; D016896:Treatment Outcome; D014551:Urinary Tract / Q000187:drug effects; D014563:Urodynamics
D058986:Phosphodiesterase 5 Inhibitors; D011744:Pyrimidinones; D013449:Sulfonamides; C528396:mirodenafil